eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

SCImago Journal & Country Rank
 
5/2013
vol. 12
 
Share:
Share:
more
 
 
abstract:
Review paper

Immunotherapy in advanced cutaneous melanoma patients

Jacek Mackiewicz
,
Łukasz Krokowicz

Przegląd Menopauzalny 2013; 17 (5): 429-433
Online publish date: 2013/11/05
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The incidence of cancer has been increasing worldwide. Melanoma is known to be one of the most immunogenic malignancies in humans. In recent years innovative and promising therapeutic strategies that modulate the immune response or target various intracellular pathways in melanoma have been developed. Recently new drugs which improved overall survival in phase III regulatory studies namely, ipilimumab (anti-CTLA-4 antibody) and vemurafenib (BRAF inhibitor) have been approved in Europe and the USA, and so has a combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in the USA for the treatment of metastatic melanoma. A number of novel immunotherapy strategies including anti-PD-1, anti-PD-1L or cancer vaccines show a durable high response rate in advanced melanoma patients, however efficacy of these drugs needs to be confirmed in phase III studies. Results from preclinical studies and early clinical trials indicate a high potential for combining immunotherapy with other treatment strategies – currently many new drug combinations are being evaluated in phase I or II in patients with metastatic melanoma.
keywords:

melanoma, immunotherapy, cancer vaccines, anti-CTLA-4, anti-PD-1

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.